Similar articles

• Perspectives for the control of cytomegalovirus infections in bone marrow transplant recipients.

  Pollard RB, Merigan TC. Pollard RB, et al. Transplant Proc. 1978 Mar;10(1):241-5. Transplant Proc. 1978. PMID: 205021 No abstract available.
• The usefulness of hyperimmune globulin for treatment of overt cytomegalovirus infection in allograft recipients.

  Rancewicz Z, Halama G, Smogorzewski M, Durlik M, Rowinska D, Lao M, Juskowa J, Wyzgal J. Rancewicz Z, et al. Transplant Proc. 1990 Aug;22(4):1818-9. Transplant Proc. 1990. PMID: 2167538 No abstract available.
• Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation.

  Fehir KM, Decker WA, Samo T, Young JB, Lederer E, Lawrence EC. Fehir KM, et al. Transplant Proc. 1989 Feb;21(1 Pt 3):3107-9. Transplant Proc. 1989. PMID: 2539691 Clinical Trial. No abstract available.
• Activation of latent viruses following bone marrow transplantation.

  Rinaldo CR Jr, Hirsch MS, Black PH. Rinaldo CR Jr, et al. Transplant Proc. 1976 Dec;8(4):669-72. Transplant Proc. 1976. PMID: 11595 Review. No abstract available.
• Cytomegalovirus infection after bone marrow transplantation in children.

  Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Castagnola E, et al. Hum Immunol. 2004 May;65(5):416-22. doi: 10.1016/j.humimm.2004.02.013. Hum Immunol. 2004. PMID: 15172440 Review.